Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease

Neurobiology of Disease

Volumn 26, Issue 2, 2007, Pages 375-384

  Ramaswamy, Shilpa ^a   McBride, Jodi L ^a   Herzog, Christopher D ^b   Brandon, Eugene ^b   Gasmi, Mehdi ^b   Bartus, Raymond T ^b   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Ceregene Inc   (United States)

Author keywords

3 Nitropropionic acid; Adenoassociated viral vector; Gene therapy; Huntington's disease; Neurturin

Indexed keywords

3 NITROPROPIONIC ACID; ENHANCED GREEN FLUORESCENT PROTEIN; GENE PRODUCT; NEURTURIN; PARVOVIRUS VECTOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; GENE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MALE; MITOCHONDRIAL TOXICITY; MOTOR PERFORMANCE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; NTN GENE; PRIORITY JOURNAL; RAT; STEREOMETRY; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CELL COUNT; CELL DEATH; CORPUS STRIATUM; CYTOPROTECTION; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUNTINGTON DISEASE; MALE; MOTOR ACTIVITY; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURONS; NEUROTOXINS; NEURTURIN; NITRO COMPOUNDS; NUCLEAR PROTEINS; PROPIONIC ACIDS; RATS; RATS, INBRED LEW; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 34147166160     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.01.003     Document Type: Article

References (33)

1. Alberch J., Perez-Navarro E., and Canals J.M. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res. Bull. 57 (2002) 817-822
2. Albin R.L., Reiner A., Anderson K.D., Dure L.S., Handelin B., Balfour R., Whetsell Jr. W.O., Penney J.B., and Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 31 (1992) 425-430
3. Alston T.A., Mela L., and Bright H.J. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. Natl. Acad Sci. U. S. A. 74 (1977) 3767-3771
4. Amtage J., and Schmidt W.J. Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behav. Pharmacol. 14 (2003) 563-567
5. Blum D., Gall D., Cuvelier L., and Schiffmann S.N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. NeuroReport 12 (2001) 1769-1772
6. Burazin T.C., and Gundlach A.L. Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum. Brain Res. Mol. Brain Res. 73 (1999) 151-171
7. Chu Y., Le W., Kompoliti K., Jankovic J., Mufson E.J., and Kordower J.H. Nurr1 in Parkinson's disease and related disorders. J. Comp. Neurol. 494 (2006) 495-514
8. Creighton S., Almqvist E.W., MacGregor D., Fernandez B., Hogg H., Beis J., Welch J.P., Riddell C., Lokkesmoe R., Khalifa M., MacKenzie J., Sajoo A., Farrell S., Robert F., Shugar A., Summers A., Meschino W., Allingham-Hawkins D., Chiu T., Hunter A., Allanson J., Hare H., Schween J., Collins L., Sanders S., Greenberg C., Cardwell S., Lemire E., MacLeod P., and Hayden M.R. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin. Genet. 63 (2003) 462-475
9. de Almeida L.P., Zala D., Aebischer P., and Deglon N. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis. 8 (2001) 433-446
10. Ducray A., Krebs S.H., Schaller B., Seiler R.W., Meyer M., and Widmer H.R. GDNF family ligands display distinct action profiles on cultured GABAergic and serotonergic neurons of rat ventral mesencephalon. Brain Res. 1069 (2006) 104-112
11. Gratacos E., Perez-Navarro E., Tolosa E., Arenas E., and Alberch J. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. J. Neurochem. 78 (2001) 1287-1296
12. Greene J.G., and Greenamyre J.T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48 (1996) 613-634
13. Hamilton J.F., Morrison P.F., Chen M.Y., Harvey-White J., Pernaute R.S., Phillips H., Oldfield E., and Bankiewicz K.S. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp. Neurol. 168 (2001) 155-161
14. Harper P.S., Morris M.J., and Tyler A. Genetic testing for Huntington's disease. BMJ 300 (1990) 1089-1090
15. Kaplitt M.G., Leone P., Samulski R.J., Xiao X., Pfaff D.W., O'Malley K.L., and During M.J. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8 (1994) 148-154
16. Koller W.C., and Davenport J. Genetic testing in Huntington's disease. Ann. Neurol. 16 (1984) 511-513
17. Lebherz C., Auricchio A., Maguire A.M., Rivera V.M., Tang W., Grant R.L., Clackson T., Bennett J., and Wilson J.M. Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum. Gene Ther. 16 (2005) 178-186
18. Lee W.T., and Chang C. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog. Neurobiol. 72 (2004) 87-110
19. Ludolph A.C., He F., Spencer P.S., Hammerstad J., and Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18 (1991) 492-498
20. Marco S., Canudas A.M., Canals J.M., Gavalda N., Perez-Navarro E., and Alberch J. Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum. Exp. Neurol. 174 (2002) 243-252
21. Marco S., Perez-Navarro E., Tolosa E., Arenas E., and Alberch J. Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease. J. Neurobiol. 50 (2002) 323-332
22. McBride J.L., During M.J., Wuu J., Chen E.Y., Leurgans S.E., and Kordower J.H. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp. Neurol. 181 (2003) 213-223
23. Oiwa Y., Yoshimura R., Nakai K., and Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res. 947 (2002) 271-283
24. Ouary S., Bizat N., Altairac S., Menetrat H., Mittoux V., Conde F., Hantraye P., and Brouillet E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 97 (2000) 521-530
25. Perez-Navarro E., Arenas E., Marco S., and Alberch J. Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur. J. Neurosci. 11 (1999) 241-249
26. Perez-Navarro E., Akerud P., Marco S., Canals J.M., Tolosa E., Arenas E., and Alberch J. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Neuroscience 98 (2000) 89-96
27. PerezNavarro E., Canudas A.M., Akerund P., Alberch J., and Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J. Neurochem. 75 (2000) 2190-2199
28. RamosArroyo M.A., Moreno S., and Valiente A. Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing. J. Neurol., Neurosurg. Psychiatry 76 (2005) 337-342
29. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., and Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad Sci. U. S. A. 85 (1988) 5733-5737
30. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., and Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11 (1999) 1554-1566
31. Silber E., Kromberg J., Temlett J.A., Krause A., and Saffer D. Huntington's disease confirmed by genetic testing in five African families. Mov. Disord. 13 (1998) 726-730
32. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
33. Xiao X., Li J., and Samulski R.J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70 (1996) 8098-8108